Candriam Luxembourg S.C.A. lessened its stake in shares of Acceleron Pharma Inc (NASDAQ:XLRN) by 38.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 73,000 shares of the biopharmaceutical company’s stock after selling 45,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Acceleron Pharma were worth $3,098,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Quantbot Technologies LP increased its holdings in Acceleron Pharma by 416.3% during the third quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 2,352 shares during the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in Acceleron Pharma during the fourth quarter worth about $138,000. Oppenheimer & Co. Inc. purchased a new stake in Acceleron Pharma during the third quarter worth about $225,000. PNC Financial Services Group Inc. increased its holdings in Acceleron Pharma by 57.8% during the second quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 3,100 shares during the last quarter. Finally, Trexquant Investment LP purchased a new stake in Acceleron Pharma during the third quarter worth about $266,000. Institutional investors and hedge funds own 85.81% of the company’s stock.
A number of analysts recently issued reports on the stock. BidaskClub upgraded shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a report on Thursday. Oppenheimer restated a “hold” rating on shares of Acceleron Pharma in a report on Monday, January 8th. HC Wainwright raised their price objective on shares of Acceleron Pharma from $57.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, November 7th. Credit Suisse Group restated an “outperform” rating and set a $55.00 price objective on shares of Acceleron Pharma in a report on Thursday, January 18th. Finally, Royal Bank of Canada restated a “hold” rating on shares of Acceleron Pharma in a report on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company. Acceleron Pharma currently has an average rating of “Buy” and a consensus target price of $44.81.
In other news, CFO Kevin F. Mclaughlin sold 4,000 shares of Acceleron Pharma stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $42.42, for a total value of $169,680.00. Following the completion of the transaction, the chief financial officer now owns 45,300 shares in the company, valued at $1,921,626. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Christopher Rovaldi sold 11,000 shares of Acceleron Pharma stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $45.00, for a total transaction of $495,000.00. Following the completion of the transaction, the senior vice president now owns 35,701 shares of the company’s stock, valued at approximately $1,606,545. The disclosure for this sale can be found here. Insiders sold 146,021 shares of company stock valued at $5,529,598 in the last quarter. Corporate insiders own 3.90% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Acceleron Pharma Inc (XLRN) Shares Sold by Candriam Luxembourg S.C.A.” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.chaffeybreeze.com/2018/02/19/acceleron-pharma-inc-xlrn-shares-sold-by-candriam-luxembourg-s-c-a.html.
Acceleron Pharma Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc (NASDAQ:XLRN).
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.